

NEWSLETTER
CHEMICAL & PHARMACEUTICAL
13 - 19 October 2025



China's tightened drug control measures bring major results

China's comprehensive drug control strategy has achieved significant results. The implementation of category-wide bans on fentanyl, synthetic cannabinoids and now nitazenes has led to a marked decline in drug abuse. The number of drug users fell 16.7% year-on-year by the end of 2024. These measures demonstrate China's commitment to combating illicit drugs and fulfilling its international obligations. **(China Daily)**

China cuts new path for commercial insurance holders to get pricey drugs

China has unveiled a new framework to help patients access expensive innovative drugs, establishing a formal list that encourages commercial health insurance to cover medicines deemed too costly for the state's basic plan. The measures aim to bridge the gap between the high price of cutting-edge pharmaceuticals and the budget constraints of the national insurance fund. **(National Healthcare Security Administration)**

China boosts medical insurance spending on innovative drugs

During the 14th Five-Year Plan period, China significantly increased its medical insurance spending on innovative drugs, with an average annual growth rate of 40%. By 2024, the expenditure on these drugs had surged to 3.9 times the level recorded in 2020. Overall, the total expenditure of the medical insurance fund during this period reached 12.13 trillion yuan (1.45 trillion euro), increasing at an average annual rate of 9.1% **(Xinhua)**

Pakistan launches second sunset review of anti-dumping investigation

On September 20, 2025, the Pakistan Customs Commission issued an update on Case No. ADC33, stating that, in response to an application filed on July 31, 2025, by Pakistani manufacturers Lucky Core Industries Limited and Ibrahim Fibers Limited, a second sunset review of anti-dumping investigations was initiated into polyester staple fiber (PSF) with a fiber fineness of 2.0 denier or less originating in or imported from China. **(China Trade Remedy Information Network)**

Pakistan initiates anti-dumping sunset review investigation on hydrogen peroxide from China

The Pakistan Customs Commission issued an updated announcement in Case No. ADC20, stating that, in response to an application submitted by Pakistani manufacturer Descon Oxychem Limited, it has initiated a third sunset review investigation into anti-dumping measures against hydrogen peroxide originating in or imported from mainland China, Taiwan, Belgium, Indonesia, South Korea, Thailand, and Turkey. **(China Trade Remedy Information Network)**